Below are the highlights of our research pipeline and the unmet medical needs each program addresses. We also summarize the research that we have undertaken in our laboratories and those of our collaborators to address these challenges. To date, two of TSRL Inc.’s technologies have been successfully out-licensed and we have secured over $21 million to invest in our portfolio assets. 

We are actively seeking partner investments and/or research collaborations to add to our portfolio of antiviral compounds as well as our drug delivery technologies.

Research Pipeline Overview

For more information, contact Business Development at bd@tsrlinc.com